BCL2 and B-cell chronic lymphocytic leukemia: CLL co‐cultures were treated with the BTK inhibitor Acalabrutinib, the PI3Kδ inhibitor Idelalisib, or the Bcl‐2 inhibitor ABT199 for 72 h, with autologous mock‐transduced T cells or CAR T cells added after 48 h and incubated for an additional 24 h in the presence of respective inhibitors.